These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 21704966

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
    Roldán-Pallarés M, Rollín R, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R.
    Retina; 2007 Feb; 27(2):222-35. PubMed ID: 17290206
    [Abstract] [Full Text] [Related]

  • 4. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H.
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J, Lu Q, Tao Y, Jiang YR.
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [Abstract] [Full Text] [Related]

  • 7. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR.
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [Abstract] [Full Text] [Related]

  • 8. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
    Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J.
    Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H.
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Soluble TNF receptors in vitreoretinal proliferative disease.
    Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH.
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
    [Abstract] [Full Text] [Related]

  • 18. Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy.
    Kawashima M, Shoji J, Nakajima M, Kamura Y, Sato Y.
    Jpn J Ophthalmol; 2007 Jun; 51(2):100-4. PubMed ID: 17401618
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy.
    Abu El-Asrar AM, Nawaz MI, Ola MS, De Hertogh G, Opdenakker G, Geboes K.
    Acta Ophthalmol; 2013 May; 91(3):e169-77. PubMed ID: 23387388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.